AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9467249 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of HBA1
Number of subjects: 37
Study 1634913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 IV on day 1 and 5‐FU 1,000 mg/m2 per day for a 96‐hour continuous infusion repeated every 21 days
Number of subjects: 277
Study 1634913 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 IV on day 1 and 5‐FU 1,000 mg/m2 per day for a 96‐hour continuous infusion repeated every 28 days
Number of subjects: 277
Study 1634913 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 40 mg/m2 IV given weekly
Number of subjects: 277
Study 1634913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus 5‐FU
Number of subjects: 277
Study 1634913 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus 5‐FU
Number of subjects: 277
Study 1634913 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 277
Study 1634913 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment assigned
Number of subjects: 277
Study 1634913 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status
Number of subjects: 277
Study 6702613 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 11
Study 6702613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30629473 — intervention group
Group type: EXPERIMENTAL
Intervention: MICRO (5-min bouts of moderate-intensity physical activity performed hourly for nine consecutive hours over 4 days)
Number of subjects: 20
Study 30629473 — intervention group
Group type: EXPERIMENTAL
Intervention: ONE (single isoenergetic 45‐min bout of moderate‐intensity exercise)
Number of subjects: 20
Study 30629473 — intervention group
Group type: COMPARATOR
Intervention: SED (sedentary condition)
Number of subjects: 20
Study 30557325 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1981
Number of subjects: 20
Study 30557325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27601419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain 3000 FIP
Number of subjects: 75
Study 27601419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain 4500 FIP
Number of subjects: 75
Study 27601419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain (pooled treatments)
Number of subjects: 75
Study 27601419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 1358498 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced glutathione (GSH) administration (1.2 g/day and 2.4 g/day intravenously)
Number of subjects: 24
Study 1358498 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide (initial dose 75‐100 mg/day)
Number of subjects: 24
Study 21780962 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive educational group intervention
Number of subjects: 50
Study 21076721 — intervention group
Group type: COMPARATOR
Intervention: 40 mg atorvastatin each night (Control group)
Number of subjects: 80
Study 21076721 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin 12 h before PCI (Low-load group)
Number of subjects: 80
Study 21076721 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin 2 h to 4 h before PCI (Mid-load group)
Number of subjects: 80
Study 21076721 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg atorvastatin 2 h to 4 h before PCI (High-load group)
Number of subjects: 80
Study 18690806 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (RVS)
Number of subjects: 21
Study 18690806 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 16308948 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 0
Study 16308948 — intervention group
Group type: COMPARATOR
Intervention: Current evidence about the impact of prostate cancer screening
Number of subjects: 0
Study 12459075 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg) with abciximab
Number of subjects: 99
Study 12459075 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (70 U/kg) with abciximab
Number of subjects: 99
Study 10506674 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 135
Study 10506674 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 135
Study 10506674 — intervention group
Group type: COMPARATOR
Intervention: Control (Social Work, CT)
Number of subjects: 135
Study 8627826 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrenal percutaneous papillotome incision under endoscopic guidance
Number of subjects: 30
Study 8627826 — intervention group
Group type: COMPARATOR
Intervention: Transrenal percutaneous papillotome incision under fluoroscopic guidance
Number of subjects: 30
Study 1932973 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day, adjusted between 5 and 40 mg)
Number of subjects: 27
Study 1932973 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg/day, adjusted between 25 and 100 mg)
Number of subjects: 27
Study 1932973 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 27
Study 1932973 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 27
Study 6660928 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (10 mg daily for 10 days, four times a year)
Number of subjects: 35
Study 6660928 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (50 mg for 10 days, four times a year)
Number of subjects: 35
Study 30171777 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal reduction
Number of subjects: 44
Study 30171777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no occlusal reduction)
Number of subjects: 44
Study 29411362 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced coughing during cervical punch biopsy
Number of subjects: 90
Study 29411362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no forced coughing)
Number of subjects: 90
Study 29411362 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced coughing during second biopsy
Number of subjects: 90
Study 29411362 — intervention group
Group type: COMPARATOR
Intervention: Control group during second biopsy
Number of subjects: 90
Study 29411362 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced coughing
Number of subjects: 90
Study 26732419 — intervention group
Group type: EXPERIMENTAL
Intervention: NID 60/80 programming for VT/VF detection
Number of subjects: 60
Study 24752196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalic trim (CT) of the lateral crura
Number of subjects: 52
Study 24752196 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal resection with cephalic hinged flap (HRCH) of the lateral crura
Number of subjects: 52
Study 24752196 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale (VAS) for global nasal obstruction
Number of subjects: 52
Study 23697214 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 92
Study 23697214 — intervention group
Group type: EXPERIMENTAL
Intervention: HD
Number of subjects: 92
Study 23697214 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 92
Study 23697214 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF patients (both CAPD and HD)
Number of subjects: 92
Study 19034051 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/d)
Number of subjects: 389
Study 19034051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 19034051 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 389
Study 22169947 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine HCl (α(2)‐adrenergic receptor antagonist) administered 30 min before acquisition
Number of subjects: 0
Study 22169947 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol HCl (β‐adrenergic receptor antagonist) administered 90 min before selective reactivation
Number of subjects: 0
Study 22169947 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol HCl administered after reactivation of the memory
Number of subjects: 0
Study 15749141 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice to stop smoking (Arm A)
Number of subjects: 918
Study 15749141 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manuals on three occasions (Arm B)
Number of subjects: 918
Study 15749141 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer program three times in addition to Arm B (Arm C)
Number of subjects: 918
Study 15749141 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control not explicitly defined)
Number of subjects: 918
Study 12042992 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE-covered nitinol stents
Number of subjects: 82
Study 11382890 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (N=21) from midnight until the end of the experiment
Number of subjects: 151
Study 11382890 — intervention group
Group type: COMPARATOR
Intervention: Standing/walking (N=27) for 15 minutes
Number of subjects: 151
Study 11382890 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (N=60) for 15 minutes
Number of subjects: 151
Study 8568287 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent live attenuated influenza A virus vaccine
Number of subjects: 50
Study 8568287 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 50
Study 1819976 — intervention group
Group type: EXPERIMENTAL
Intervention: LOPP (chlorambucil, vincristine, prednisone, procarbazine)
Number of subjects: 83
Study 1819976 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, prednisone)
Number of subjects: 83
Study 1819976 — intervention group
Group type: EXPERIMENTAL
Intervention: LOPP
Number of subjects: 83
Study 1819976 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 83
Study 7140133 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg IV propranolol
Number of subjects: 10
Study 7140133 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 mg/kg oral propranolol
Number of subjects: 10
Study 7140133 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg IV timolol
Number of subjects: 10
Study 7140133 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg oral timolol
Number of subjects: 10
Study 7140133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29368622 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool Situational Self-Regulation Toolkit (PRSIST) program implemented by early childhood educators
Number of subjects: 50
Study 29368622 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (Control group)
Number of subjects: 50
Study 29368622 — intervention group
Group type: EXPERIMENTAL
Intervention: PRSIST program
Number of subjects: 50
Study 27646496 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 87
Study 27646496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 87
Study 27646496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 26553830 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 403
Study 23973126 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 360
Study 23973126 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐12 Mental Component Summary (MCS) score <40
Number of subjects: 360
Study 23973126 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐12 Physical Component Summary (PCS) score <50
Number of subjects: 360
Study 23973126 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐manual labour
Number of subjects: 360
Study 23973126 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual labour
Number of subjects: 360
Study 23973126 — intervention group
Group type: EXPERIMENTAL
Intervention: High maximum knee pain (4‐6 out of 10)
Number of subjects: 360
Study 20835577 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatine Endodontic Cleanser (Aquatine EC) with EDTA rinse
Number of subjects: 45
Study 20835577 — intervention group
Group type: COMPARATOR
Intervention: 6% sodium hypochlorite (NaOCl) with EDTA rinse
Number of subjects: 45
Study 18157962 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 86
Study 18157962 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 86
Study 16024564 — intervention group
Group type: EXPERIMENTAL
Intervention: Down syndrome (DS) subjects
Number of subjects: 20
Study 16024564 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 16024564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DS and control)
Number of subjects: 20
Study 14646609 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (alpha-2 adrenoreceptor antagonist)
Number of subjects: 18
Study 10383505 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐0966 250 mg q.d.
Number of subjects: 170
Study 10383505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg t.d.s.
Number of subjects: 170
Study 10383505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg q.d.s.
Number of subjects: 170
Study 10383505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 8678131 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg per day
Number of subjects: 26
Study 8678131 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens 0.625 mg per day and medroxyprogesterone 2.5 mg per day
Number of subjects: 26
Study 1874219 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and alfentanil
Number of subjects: 57
Study 1874219 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone and alfentanil
Number of subjects: 57
Study 6131487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tardive dyskinesia (TD) group
Number of subjects: 0
Study 6131487 — intervention group
Group type: COMPARATOR
Intervention: Non-tardive dyskinesia (NTD) group
Number of subjects: 0
Study 31978815 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 120
Study 31978815 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic regimen
Number of subjects: 120
Study 30037045 — intervention group
Group type: COMPARATOR
Intervention: 0 g of mixed spices
Number of subjects: 17
Study 30037045 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of mixed spices
Number of subjects: 17
Study 30037045 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g of mixed spices
Number of subjects: 17
Study 27109202 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-led, team-based model of strategies
Number of subjects: 1265
Study 27109202 — intervention group
Group type: COMPARATOR
Intervention: Routine patient change-over (Control)
Number of subjects: 1265
Study 23508540 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy plus polyglactin 910 mesh (vaginal)
Number of subjects: 70
Study 23508540 — intervention group
Group type: COMPARATOR
Intervention: Paravaginal defect repair (abdominal)
Number of subjects: 70
Study 23508540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 21924957 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Me Healthy (CMH) curriculum
Number of subjects: 263
Study 21924957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CMH curriculum)
Number of subjects: 263
Study 20033276 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention (audiovisual message)
Number of subjects: 260
Study 20033276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 260
Study 18724192 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator supervision based on the Eban Theoretical Framework for Supervision
Number of subjects: 0
Study 18724192 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 16228125 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniocervical junction decompression (CCJD)
Number of subjects: 15
Study 16228125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasyringeal CSF pulsatile motion
Number of subjects: 15
Study 12537629 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 0
Study 9708607 — intervention group
Group type: EXPERIMENTAL
Intervention: Falecalcitriol
Number of subjects: 25
Study 9708607 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 25
Study 8551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep nasendoscopy (SN)
Number of subjects: 53
Study 8551147 — intervention group
Group type: COMPARATOR
Intervention: No sleep nasendoscopy (Control group A)
Number of subjects: 53
Study 8551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep nasendoscopy (SN) for palatal snorers
Number of subjects: 53
Study 2223425 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 12
Study 2223425 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 12
Study 2223425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 359255 — intervention group
Group type: EXPERIMENTAL
Intervention: Difunisal (250 mg or 500 mg twice daily for 5 days)
Number of subjects: 1902
Study 359255 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (600 mg four times daily for 5 days)
Number of subjects: 1902
Study 31542737 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan Well Guide decision aid administered to the patient by a facilitator with the SDM present.
Number of subjects: 90
Study 31542737 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan Well Guide decision aid
Number of subjects: 90
Study 28122933 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding (FF)
Number of subjects: 728
Study 28122933 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding <3 mo (EBF <3 mo)
Number of subjects: 728
Study 25577661 — intervention group
Group type: COMPARATOR
Intervention: Consistent limb group (DTaP-IPV-Hib and PCV13 administered to the right leg)
Number of subjects: 509
Study 25577661 — intervention group
Group type: COMPARATOR
Intervention: Consistent limb group
Number of subjects: 509
Study 25577661 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating limb group (DTaP-IPV-Hib and PCV13 administered to alternating limbs)
Number of subjects: 509
Study 25577661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 509
Study 23714397 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental awareness training for care coordinators plus a dental checklist for service users in addition to standard care
Number of subjects: 10
Study 23714397 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 10
Study 21292088 — intervention group
Group type: EXPERIMENTAL
Intervention: MSBR + HGF (intravenous 150 μg/kg per day)
Number of subjects: 45
Study 21292088 — intervention group
Group type: EXPERIMENTAL
Intervention: MSBR
Number of subjects: 45
Study 21292088 — intervention group
Group type: COMPARATOR
Intervention: Control (sham operation)
Number of subjects: 45
Study 18706460 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal PCO2 measurement
Number of subjects: 0
Study 18706460 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous PCO2 measurement
Number of subjects: 0
Study 18706460 — intervention group
Group type: EXPERIMENTAL
Intervention: Paused breathing (hypoventilation)
Number of subjects: 0
Study 17919488 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g oleic acid (FFA, 1830 kJ)
Number of subjects: 9
Study 17919488 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g macadamia oil (TG, 1856 kJ)
Number of subjects: 9
Study 17919488 — intervention group
Group type: COMPARATOR
Intervention: 600 mL 4% milk protein (control, 352 kJ)
Number of subjects: 9
Study 15490072 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy at a dose of 0.25 U/kg body weight/week for 72 months
Number of subjects: 20
Study 15490072 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 20
Study 15490072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11876011 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, aqueous nasal spray, 400 micrograms per day, administered every 12 hours for 6 weeks
Number of subjects: 55
Study 11876011 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 55
Study 9697378 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide three times daily
Number of subjects: 81
Study 9697378 — intervention group
Group type: COMPARATOR
Intervention: 2% pilocarpine four times daily
Number of subjects: 81
Study 8042862 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Acyclovir (ACV) plus 348U87, initiated immediately after UV exposure
Number of subjects: 34
Study 8042862 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 2665093 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 20
Study 2665093 — intervention group
Group type: COMPARATOR
Intervention: Conservative-functional treatment with a newly developed shoe
Number of subjects: 20
Study 798654 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily occlusive applications of butylated hydroxytoluene for 60 days
Number of subjects: 16
Study 31324213 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (i-gel®)
Number of subjects: 1150
Study 31324213 — intervention group
Group type: COMPARATOR
Intervention: Face mask ventilation
Number of subjects: 1150
Study 29190604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry extract (300 mg/d, twice per day for 12 weeks)
Number of subjects: 60
Study 25320864 — intervention group
Group type: EXPERIMENTAL
Intervention: Looming threat condition with high dispositional and comparative optimism
Number of subjects: 0
Study 25320864 — intervention group
Group type: COMPARATOR
Intervention: Looming threat condition with high dispositional but low comparative optimism
Number of subjects: 0
Study 25320864 — intervention group
Group type: EXPERIMENTAL
Intervention: Looming threat condition
Number of subjects: 0